Strides Pharma Science Reports 17% Revenue Growth, Ex-US Markets Lead Q2 FY27
Strides Pharma Science Ltd reported a 17.1% year-on-year revenue increase to Rs 1,429.7 crore for Q2 FY27, with Ex-US markets growing 31% to Rs 696.3 crore, surpassing the US business, which grew 9%. EBITDA rose 8.4% to Rs 250.9 crore, crossing Rs 250 crore for the first time in a quarter. Profit after tax increased 2% to Rs 134.1 crore despite higher raw material and freight costs. The company highlighted its diversification strategy and ongoing cost optimization amid geopolitical challenges.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 36/100.
Outlets measured: freepressjournal, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 29 Oct, 03:16 pm. Other outlets followed.
- 1